Global CD3 Antibodies Market 2023-2028: New-Generation CD3 Antibodies Targeting Diverse Indications Gain Ground
02 nov. 2023 07h43 HE
|
Research and Markets
Dublin, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The "Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. ...
Wistar Scientists Engineer New NK cell Engaging Immunotherapy Approaches to Target and potentially Treat recalcitrant Ovarian Cancer
01 nov. 2023 14h54 HE
|
The Wistar Institute
PHILADELPHIA, PA, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Wistar Institute’s David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center (VIC) and W.W. Smith...
Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)
01 nov. 2023 12h46 HE
|
Siren Biotechnology, Inc.
Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
31 oct. 2023 09h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two...
Outpace Bio to Present New Data on Tumor-restricted IL-12 Designed Leveraging OutSmart Technology to Enhance Solid Tumor T Cell Therapies at SITC 2023
31 oct. 2023 09h00 HE
|
Outpace Bio
Seattle, WA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Outpace Bio, a cell therapy company that is solving the major barriers to curing solid tumors with AI-powered protein design, today announced it will...
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
26 oct. 2023 09h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, today reports novel findings for its lead product, pepinemab, in a...
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
24 oct. 2023 07h00 HE
|
https://immatics.com/
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer typesRegulatory activities...
EvolveImmune Therapeutics to Present New Preclinical and Translational Data Highlighting Precision Medicine Potential of its Novel Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
18 oct. 2023 07h00 HE
|
EvolveImmune
EvolveImmune to Highlight New Data on Precision Medicine Potential of Evolve Platform and Lead Development Programs in Presentations at SITC 2023
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
17 oct. 2023 07h00 HE
|
AC Immune SA
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference Lausanne, Switzerland, October 17, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...
Antion Biosciences Announces Presentation of Two Abstracts from its Multiplex Cell Engineering Platform at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
17 oct. 2023 06h55 HE
|
ANTION BIOSCIENCES SA
Functional demonstration of Antion’s uniquely capable technology to develop allogeneic anti-CD19 CAR T-cells with “tuned” silencing of HLA-I Latest advancements in the application of Antion’s miCAR...